Ariad Pharmaceuticals Inc. Forecasted to Earn Q3 2016 Earnings of ($0.17) Per Share (ARIA)
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) – SunTrust Banks issued their Q3 2016 EPS estimates for Ariad Pharmaceuticals in a note issued to investors on Tuesday. SunTrust Banks analyst Y. Suneja anticipates that the brokerage will post earnings of ($0.17) per share for the quarter. SunTrust Banks has a “Buy” rating on the stock. SunTrust Banks also issued estimates for Ariad Pharmaceuticals’ Q4 2016 earnings at ($0.20) EPS, FY2016 earnings at ($0.09) EPS, Q1 2017 earnings at ($0.20) EPS, Q2 2017 earnings at ($0.20) EPS, Q3 2017 earnings at ($0.21) EPS, Q4 2017 earnings at ($0.91) EPS, FY2017 earnings at $0.48 EPS, FY2018 earnings at $0.58 EPS, FY2019 earnings at $1.15 EPS and FY2020 earnings at $2.02 EPS.
Ariad Pharmaceuticals (NASDAQ:ARIA) last issued its quarterly earnings data on Thursday, July 28th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.70. The firm earned $65.30 million during the quarter, compared to analyst estimates of $60.64 million. During the same period in the prior year, the company earned ($0.28) earnings per share. The business’s quarterly revenue was up 133.0% compared to the same quarter last year.
A number of other analysts also recently issued reports on ARIA. Cowen and Company reissued an “outperform” rating and issued a $10.00 target price on shares of Ariad Pharmaceuticals in a research report on Tuesday, June 21st. Royal Bank Of Canada reissued a “hold” rating on shares of Ariad Pharmaceuticals in a research report on Monday, June 20th. Jefferies Group reissued a “buy” rating and issued a $13.00 target price on shares of Ariad Pharmaceuticals in a research report on Wednesday, June 22nd. Zacks Investment Research raised Ariad Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a research report on Tuesday, July 5th. Finally, Barclays PLC raised their target price on Ariad Pharmaceuticals from $8.00 to $9.00 and gave the stock an “underweight” rating in a research report on Friday, July 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $10.13.
Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 13.35 on Thursday. The firm has a 50-day moving average price of $11.72 and a 200-day moving average price of $8.77. Ariad Pharmaceuticals has a one year low of $4.37 and a one year high of $14.26. The firm’s market capitalization is $2.57 billion.
In other Ariad Pharmaceuticals news, insider Timothy P. Clackson sold 18,286 shares of Ariad Pharmaceuticals stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $8.11, for a total transaction of $148,299.46. Following the completion of the sale, the insider now owns 248,208 shares of the company’s stock, valued at $2,012,966.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Timothy P. Clackson sold 8,750 shares of Ariad Pharmaceuticals stock in a transaction dated Wednesday, September 28th. The stock was sold at an average price of $13.98, for a total value of $122,325.00. Following the sale, the insider now directly owns 226,272 shares of the company’s stock, valued at approximately $3,163,282.56. The disclosure for this sale can be found here. Corporate insiders own 8.20% of the company’s stock.
Large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its stake in shares of Ariad Pharmaceuticals by 6.7% in the second quarter. Ameritas Investment Partners Inc. now owns 13,787 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 866 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Ariad Pharmaceuticals during the second quarter valued at about $107,000. BNP Paribas Arbitrage SA raised its stake in shares of Ariad Pharmaceuticals by 110.4% in the third quarter. BNP Paribas Arbitrage SA now owns 14,629 shares of the pharmaceutical company’s stock valued at $200,000 after buying an additional 7,675 shares during the period. Seven Eight Capital LLC purchased a new stake in shares of Ariad Pharmaceuticals during the second quarter valued at about $117,000. Finally, Fiera Capital Corp purchased a new stake in shares of Ariad Pharmaceuticals during the second quarter valued at about $118,000. 71.99% of the stock is owned by hedge funds and other institutional investors.
Ariad Pharmaceuticals Company Profile
ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Receive News & Stock Ratings for Ariad Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.